1. Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy 
Narek Shaverdian, MD, Darlene Veruttipong, MPH, Jason Wang, PhD, MS, Patrick Kupelian, MD, Michael Steinberg, MD, Percy Lee, MD 
Journal of Thoracic Oncology 
Volume 11, Issue 8, Pages (August 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Kaplan-Meier analysis was used to determine 3-year local, regional, and distant control rates (A), disease-free survival (B), and overall survival (C) of patients with early-stage non–small cell lung cancer treated definitively with stereotactic body radiation therapy.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Receiver operating characteristic (ROC) analysis was used to determine the optimal pretreatment hemoglobin (Hgb) cutoff value that would predict regional control (A) and disease-free survival (B) with an area under the curve (AUC) of 0.70 for regional control and 0.72 for disease-free survival. A pretreatment Hgb value less than 12.2 g/dL was found to optimally predict for poor regional control and disease-free survival.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Kaplan-Meier analysis was used to compare the 3-year regional control (A) and disease-free survival (B) of patients with a pretreatment hemoglobin (Hgb) value less than 12.2 g/dL versus 12.2 g/dL or higher.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions